We leverage mass spectrometry in targeted proteomics studies to deliver robust, quantitative measure of protein(s) and proteoform(s) of interest.
Sapient’s offers targeted protein assays and panels to deliver precise, robust insights that inform and accelerate all phases of drug development – from PK/PD studies to clinical biomarker monitoring. Explore the key differentiators of our targeted proteomics approach:
Eliminates cross-reactivity and non-specific binding while saving lengthy antibody development time.
Our off-the-shelf assays encompass >12K proteins which can undergo full validation based on your specific study.
Amenable to plasma/serum, tissue, tumors, CSF, urine, saliva, eye fluid, cells, media, and more.
Sapient’s high throughput mass spectrometry systems
allow us to deliver precision protein measures at scale,
processing hundreds of samples per day and providing an ideal solution for detecting and monitoring protein targets and biomarkers in clinical settings.
Our mass spectrometry method leverages labeled peptides for direct, absolute quantitation of proteins of interest in virtually any sample matrix. This targeted proteomics approach:
Don’t see your protein of interest? Sapient can perform custom assay development for bespoke & difficult-to-measure proteins, protein variants, and PTMs, including for multiplexed panels.
Innovative new drug modalities are now able to target disease-modifying proteins once considered too challenging to reach. Sapient’s assays allow you to readily detect and quantify more proteins in the expanding druggable space.
For questions or to discuss a specific project, we encourage you to book a time to talk to our scientific team.
"*" indicates required fields
